Department of Pulmonary Diseases, Department of Intensive Care Medicine and Home Mechanical Ventilation, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands.
Department of Home Mechanical Ventilation, Erasmus Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
BMC Pulm Med. 2022 Nov 9;22(1):410. doi: 10.1186/s12890-022-02195-5.
In the current study, we undertook a more detailed exploration of the reasons why patients undergoing HMV were screened out of a recently published study in order to better understand how applicable home initiation of HMV is under real life conditions.
All referred patients who had an indication for starting HMV were screened to participate in the Homerun study. In this trial 512 patients were screened out of the study. Those patients not enrolled in the trial were divided into the following 3 groups: (1) those not fulfilling the inclusion criteria; 2) those meeting the exclusion criteria and 3) those excluded on the basis of medical or organisation reasons. Each group was then further divided into those who would likely have been suitable for initiation of HMV at home in real world practice and those who were unsuitable.
Based on inclusion criteria (group 1) 116 patients could not start HMV in real life, while this was 245 patients in the study. Based on the exclusion criteria (group 2) 11 patients could not start in real life while this was 79 in the study. One hundred and eighty-eight could not be enrolled in the study due to medical and organisational reasons ( group 3), while in real life this was only 95.
This study indicates that more than 55% of patients who did not participate in the Homerun study could have started HMV at home in real life.
在本研究中,我们更详细地探讨了在最近发表的一项研究中被筛选出接受 HMV 的患者的原因,以便更好地了解在实际生活条件下家庭启动 HMV 的适用性。
所有有启动 HMV 指征的转诊患者均被筛选参加 Homerun 研究。在该试验中,有 512 名患者被筛选出该研究。未纳入试验的患者分为以下 3 组:(1)不符合纳入标准的患者;(2)符合排除标准的患者;(3)基于医疗或组织原因排除的患者。然后,每个组进一步分为在真实世界实践中可能适合家庭启动 HMV 的患者和不适合的患者。
根据纳入标准(组 1),116 名患者在真实生活中无法启动 HMV,而在研究中这一数字为 245 名。根据排除标准(组 2),11 名患者在真实生活中无法启动 HMV,而在研究中这一数字为 79 名。由于医疗和组织原因,188 名患者无法纳入研究(组 3),而在真实生活中这一数字仅为 95 名。
这项研究表明,在 Homerun 研究中未参与的患者中,有超过 55%的患者在真实生活中可能已经开始接受 HMV 治疗。